Impax Laboratories Inc. (IPXL)

17.90
0.22 1.24
NYSE : Health Technology
Prev Close 17.68
Open 17.72
Day Low/High 17.50 / 18.29
52 Wk Low/High 13.47 / 18.29
Volume 839.29K
Avg Volume 916.90K
Exchange NYSE
Shares Outstanding 73.87M
Market Cap 1.35B
EPS -6.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Impax Pharmaceuticals Initiates Phase IIb Trial Of IPX159 In Restless Legs Syndrome

Impax Pharmaceuticals Initiates Phase IIb Trial Of IPX159 In Restless Legs Syndrome

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories To Present At The Piper Jaffray 23rd Annual Healthcare Conference

Impax Laboratories To Present At The Piper Jaffray 23rd Annual Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Piper Jaffray 23rd Annual Healthcare Conference on Wednesday, November 30, at 3:00 p.

Impax Laboratories Confirms Patent Challenge Relating To Generic FENTORA®

Impax Laboratories Confirms Patent Challenge Relating To Generic FENTORA®

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with Fentora® (fentanyl buccal tablets, 100 mcg, 200 mcg, 400 mcg,...

Impax Laboratories To Present At The Credit Suisse 2011 Healthcare Conference

Impax Laboratories To Present At The Credit Suisse 2011 Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Credit Suisse 2011 Healthcare Conference on Friday, November 11, at 8:00 a.

Impax Laboratories Reports Third Quarter 2011 Financial Results

Impax Laboratories Reports Third Quarter 2011 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported third quarter ended September 30, 2011 financial results.

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2011 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Third Quarter 2011 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its third quarter 2011 financial results will be released before the market opens on Tuesday, November 1, 2011 and will be available on Impax’s Web ...

Impax Laboratories To Present At The Jefferies Global Healthcare Conference In London

Impax Laboratories To Present At The Jefferies Global Healthcare Conference In London

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, September 27, at 1:00 pm BST (8:00 a.

Impax Laboratories To Present At The UBS Global Life Sciences Conference

Impax Laboratories To Present At The UBS Global Life Sciences Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Life Sciences Conference on Tuesday, September 20, at 7:30 a.

Impax Laboratories Confirms Patent Challenge Relating To Generic JALYN® 0.5 Mg/0.4 Mg

Impax Laboratories Confirms Patent Challenge Relating To Generic JALYN® 0.5 Mg/0.4 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in connection with JALYN® (dutasteride and tamsulosin hydrochloride 0.

Impax Laboratories Appoints Carole Ben-Maimon, M.D. President Of Global Pharmaceuticals

Impax Laboratories Appoints Carole Ben-Maimon, M.D. President Of Global Pharmaceuticals

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today the appointment of Carole Ben-Maimon, M.

Impax Laboratories Confirms Patent Challenge Relating To Generic NUEDEXTA® 20 Mg/10 Mg

Impax Laboratories Confirms Patent Challenge Relating To Generic NUEDEXTA® 20 Mg/10 Mg

Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in connection with Nuedexta® (dextromethorphan hydrobromide and quinidine sulfate 20 mg / 10 mg)...

Impax Laboratories Inc. Stock Downgraded (IPXL)

Impax Laboratories Inc. Stock Downgraded (IPXL)

Impax Laboratories (Nasdaq:IPXL) has been downgraded by TheStreet Ratings from from a buy to hold.

Impax Stock Gaps Up On Today's Open (IPXL)

Impax Stock Gaps Up On Today's Open (IPXL)

Shares of Impax Laboratories (Nasdaq:IPXL) were gapping up Monday morning with an open price 12.5% higher than Friday's closing price. The stock closed at $16.80 yesterday and opened today's trading at $18.90.

Http://www.gsk.com

Http://www.gsk.com

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories Reports Second Quarter 2011 Financial Results

Impax Laboratories Reports Second Quarter 2011 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) today reported second quarter ended June 30, 2011 financial results.

Impax Pharmaceuticals Completes Enrollment In ASCEND-PD Phase III Trial Of IPX066 In Parkinson’s Disease

Impax Pharmaceuticals Completes Enrollment In ASCEND-PD Phase III Trial Of IPX066 In Parkinson’s Disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Pharmaceuticals Awarded Michael J. Fox Foundation Grant For Ongoing Research Of IPX066 For Parkinson’s Disease

Impax Pharmaceuticals Awarded Michael J. Fox Foundation Grant For Ongoing Research Of IPX066 For Parkinson’s Disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2011 Financial Results

Impax Laboratories Schedules Conference Call And Webcast For Second Quarter 2011 Financial Results

Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that its second quarter 2011 financial results will be released before the market opens on Tuesday, August 2, 2011 and will be available on Impax’s Web ...

Impax Laboratories Announces Settlement Of Litigation Relating To WELCHOL® Tablets And WELCHOL® Oral Suspension Products

Impax Laboratories Announces Settlement Of Litigation Relating To WELCHOL® Tablets And WELCHOL® Oral Suspension Products

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has reached agreement with Daiichi Sankyo, Inc.

Impax Laboratories Strengthens Leadership By Adding New Senior Vice Presidents For Global Operations And Global Quality Affairs

Impax Laboratories Strengthens Leadership By Adding New Senior Vice Presidents For Global Operations And Global Quality Affairs

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced two executive appointments that will strengthen the company’s leadership in the critical areas of operations and quality affairs.

Impax Laboratories To Present At The Wells Fargo Securities Healthcare Conference

Impax Laboratories To Present At The Wells Fargo Securities Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the 2011 Wells Fargo Securities Healthcare Conference on Thursday, June 23, at 8:30 a.

Impax Laboratories Provides An Update On Recent FDA Site Inspection

Impax Laboratories Provides An Update On Recent FDA Site Inspection

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that late Friday, June 3, it received a warning letter from the U.

Impax Laboratories To Present At The Jefferies 2011 Global Healthcare Conference

Impax Laboratories To Present At The Jefferies 2011 Global Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Jefferies 2011 Global Healthcare Conference on Thursday, June 9, at 9:00 a.

Impax Laboratories Confirms Patent Suit Relating To Generic Detrol® Immediate-Release 1 Mg And 2 Mg Tablets

Impax Laboratories Confirms Patent Suit Relating To Generic Detrol® Immediate-Release 1 Mg And 2 Mg Tablets

Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that Pfizer Inc.

Impax Laboratories To Present At The Goldman Sachs Annual Global Healthcare Conference

Impax Laboratories To Present At The Goldman Sachs Annual Global Healthcare Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Goldman Sachs 32 nd Annual Global Healthcare Conference on Tuesday, June 7, at 1:20 p.

Impax Laboratories Announces Voting Results From 2011 Annual Meeting Of Stockholders

Impax Laboratories Announces Voting Results From 2011 Annual Meeting Of Stockholders

Impax Laboratories, Inc. (NASDAQ: IPXL) held its 2011 Annual Meeting of Stockholders yesterday in San Mateo, California.

Impax Pharmaceuticals Provides An Update On Pipeline Candidate IPX159

Impax Pharmaceuticals Provides An Update On Pipeline Candidate IPX159

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc.

Impax Laboratories Confirms Patent Suit Relating To Generic Concerta® 18, 27 And 36 Mg Tablets

Impax Laboratories Confirms Patent Suit Relating To Generic Concerta® 18, 27 And 36 Mg Tablets

Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that Alza Corporation has filed suit for patent infringement against Impax in the United States District Court for the District of Delaware in connection with...

Impax Laboratories To Present At The Bank Of America Merrill Lynch 2011 Health Care Conference

Impax Laboratories To Present At The Bank Of America Merrill Lynch 2011 Health Care Conference

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch 2011 Health Care Conference on Thursday, May 12, at 11:10 a.